Interestingly, tumour cell surface expression of HLA-E is sensitive to downregulation by various clinically relevant pharmacological agents such as the XPO1 inhibitor selinexor, the proteosome inhibitor bortezomib, and the cyclin-dependent kinase inhibitor dinaciclib [112, 121–123]. Here, HLA-E is linked to neoplasm.